Drugs / Macupatide
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06557356 | Aug 2024 → Dec 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05887999 | Jun 2023 → Feb 2024 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05407961 | Jun 2022 → Jan 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04923269 | Jun → Oct 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07589608 | May 2026 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07215559 | Oct 2025 → Mar 2027 expected | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06143956 | Nov 2023 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Macupatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215559 ↗ |
| Known as | LY3532226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05407961 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068487 ↗ |
| Route | Subcutaneous | “Single ascending doses of LY3532226 administered subcutaneously (SC).” NCT04923269 ↗ |